健康状况
18 基于循证研究的健康状况与补充剂信息
Explore health conditions with evidence-graded supplement recommendations. Each condition page ranks ingredients by the strength of clinical research supporting them.
How We Grade Evidence
每个健康状况页面按临床证据强度对补充剂成分进行排序。以下是各等级的含义:
Strong Evidence
Multiple randomized controlled trials (RCTs) or meta-analyses with consistent positive results and large sample sizes.
Good Evidence
At least one RCT with mostly consistent results across studies. Evidence suggests benefit but more research may be needed.
Some Evidence
Small studies or observational data with some positive signals. Promising but insufficient for strong recommendations.
Very Early Research
In vitro studies, case reports, or pilot studies only. Early-stage research that requires clinical validation.
Acute Bronchitis
5% of adults annually
Allergic Rhinitis
10-30% of adults globally; 40% of children
Gut Immune Health
Gut dysbiosis affects an estimated 25-45% of adults
Post-Viral Fatigue
10-35% of individuals after certain viral infections; ~10% post-COVID
Chronic Inflammation
Estimated 50-60% of adults have at least one inflammatory biomarker elevation
Recurrent Infections
~25% of primary care patients report recurrent infections
Oxidative Stress
Universal physiological process; pathological levels associated with chronic disease
Stress-Related Immune Suppression
Chronic stress affects 70-80% of working adults
Vaccine Response Support
Suboptimal vaccine responses in 30-50% of elderly adults
Pediatric Immune Support
6-8 URTIs per year in children under 6
Exercise-Induced Immune Suppression
Affects endurance athletes and those in heavy training
Sinusitis
31 million episodes annually in the US
Wound Healing and Immune Recovery
50 million surgical procedures annually in the US require immune recovery support
Skin Immune Barrier
Compromised skin barrier affects 15-20% of adults (eczema, dermatitis)
Upper Respiratory Tract Infections
2-4 episodes/year in adults; 6-8 in children
Influenza
5-15% of global population annually
Immune Aging (Immunosenescence)
Affects all individuals with aging; clinically significant after age 65
Autoimmune Conditions
5-8% of the population; >80 recognized autoimmune diseases
FDA 免责声明: 这些声明未经美国食品药品监督管理局(FDA)评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析,不构成医疗建议。在开始任何补充剂方案之前,请务必咨询您的医疗保健提供者。